Kiniksa Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Kiniksa Pharmaceuticals has a total shareholder equity of $438.8M and total debt of $12.3M, which brings its debt-to-equity ratio to 2.8%. Its total assets and total liabilities are $526.3M and $87.5M respectively.
Key information
2.8%
Debt to equity ratio
US$12.26m
Debt
| Interest coverage ratio | n/a |
| Cash | US$206.37m |
| Equity | US$438.84m |
| Total liabilities | US$87.48m |
| Total assets | US$526.32m |
Recent financial health updates
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17Recent updates
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Nov 30Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
Nov 16Financial Position Analysis
Short Term Liabilities: KNSA's short term assets ($276.3M) exceed its short term liabilities ($63.7M).
Long Term Liabilities: KNSA's short term assets ($276.3M) exceed its long term liabilities ($23.8M).
Debt to Equity History and Analysis
Debt Level: KNSA has more cash than its total debt.
Reducing Debt: KNSA's debt to equity ratio has increased from 0% to 2.8% over the past 5 years.
Debt Coverage: KNSA's debt is well covered by operating cash flow (108.5%).
Interest Coverage: Insufficient data to determine if KNSA's interest payments on its debt are well covered by EBIT.